Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00675025 · ClinicalTrials.gov registry record · Phase 2
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
A Phase 2 study, sponsored by Eisai.
- Terminated
- Registry status
- Phase 2
- Development phase
- 117
- Enrollment target
NCT00675025 is a Phase 2 study that was terminated before completion, run by Eisai. The registered enrollment target is 117 participants.
The verdict
NCT00675025, a Phase 2 study, was terminated before completion, sponsored by Eisai.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 117 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of donepezil hydrochloride (Aricept) in children with Down syndrome who have finished the preceding 10-week, double-blind study of donepezil hydrochloride. Medical tests for drug safety will be conducted at each clinic visit.
Interventions
- DRUG Donepezil hydrochloride (Aricept)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2008-04-04 |
| Est. Completion | 2008-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00675025
The ClinicalTrials.gov registry entry for NCT00675025 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Donepezil hydrochloride (Aricept) is the first listed.
NCT00675025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00675025 about?
NCT00675025 is a clinical study titled "Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial". The purpose of this study is to determine the safety of donepezil hydrochloride (Aricept) in children with Down syndrome who have finished the preceding 10-week, double-blind study of donepezil hydrochloride. Medical tests for drug safety will be conducted at each clinic visit.
What is the current status of trial NCT00675025?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 117 participants. The study started on 2008-04-04. Estimated completion is 2008-12-15.
What interventions are being tested in trial NCT00675025?
The interventions under investigation include: Donepezil hydrochloride (Aricept) (DRUG).
Who is sponsoring clinical trial NCT00675025?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.